XTalks

MAY 26, 2023

DEB is a genetic disorder characterized by very fragile skin that rips and blisters easily even from minor friction (like rubbing or scratching) or injury, resulting in open wounds that are prone to skin infections and fibrosis. Vyjuvek is also the first drug approved to treat the disease and is Krystal’s first approved product.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

The Pharma Data

DECEMBER 3, 2020

Dravet syndrome is a severe and progressive genetic epilepsy characterized by frequent, prolonged and refractory seizures that usually begin within the first year of life. December 5, 2:00 PM – 3:30 PM; Platform A: Translational Research / Genetics. Genetics / 12A. –( BUSINESS WIRE )– Stoke Therapeutics , Inc.

Medicine 52

Medicine Genetics Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 18, 2021

The BTK protein sends important signals that tell B cells to mature and produce antibodies. Call your doctor for medical advice about side effects. About VENCLEXTA ® /VENCLYXTO ® (venetoclax) VENCLEXTA ® /VENCLYXTO ® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein.

Medicine 40

Medicine Production FDA Approval Trials 40

The Pharma Data

JUNE 18, 2021

The BTK protein sends important signals that tell B cells to mature and produce antibodies. VENCLEXTA ® /VENCLYXTO ® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. VENCLXEXTA/VENCLYXTO targets the BCL-2 protein and works to help restore the process of apoptosis.

Medicine 52

Medicine Production FDA Approval Trials 52

The Pharma Data

MAY 14, 2021

All the scientific studies… And the words straight from a doctor’s mouth… So you’ll have everything you need… By the way, my name is Matt Stirling. It’s all based on human biology… I refer to it as your “metabolism switch”… But the scientific name for it is AMP-activated protein kinase….

Production 52

Production Insulin Packaging Packaging 52

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92